Last updated: August 8, 2026
Sulfamethoxazole and trimethoprim is a mature, low-cost antibacterial combination with limited patent protection and substantial formulation opportunity. The commercial value is concentrated in oral suspensions, high-strength tablets, hospital injection products, pediatric delivery, taste masking, preservative selection, packaging, and supply reliability rather than molecule-level exclusivity.
The combination is commonly called co-trimoxazole and is marketed under legacy brands including Bactrim and Septra. The standard ratio is 5:1 sulfamethoxazole to trimethoprim. U.S. products include immediate-release tablets, oral suspension, and intravenous injection. FDA-approved generic competition is extensive.[1][2]
What is the FDA regulatory status of sulfamethoxazole and trimethoprim?
Sulfamethoxazole and trimethoprim are approved antibacterial drugs available through abbreviated new drug applications and legacy branded products. The principal U.S. dosage forms are:
| Dosage form |
Typical strength |
Common administration |
| Single-strength tablet |
400 mg sulfamethoxazole / 80 mg trimethoprim |
Oral |
| Double-strength tablet |
800 mg sulfamethoxazole / 160 mg trimethoprim |
Oral |
| Oral suspension |
200 mg sulfamethoxazole / 40 mg trimethoprim per 5 mL |
Oral |
| IV injection |
400 mg sulfamethoxazole / 80 mg trimethoprim per 5 mL |
Intravenous |
The combination is indicated for selected urinary tract infections, otitis media, shigellosis, Pneumocystis jirovecii pneumonia treatment and prophylaxis, and other susceptible infections. Use is constrained by hypersensitivity, severe renal impairment, hyperkalemia risk, drug interactions, hematologic toxicity, and serious skin reactions.[2][3]
The FDA Orange Book identifies reference-listed drug products and approved generic equivalents. The combination is a mature multisource product. Current commercial competition is primarily between generic manufacturers, contract manufacturers, hospital suppliers, and pharmacy distributors rather than between innovator and generic products.[1]
When does sulfamethoxazole and trimethoprim lose exclusivity?
Sulfamethoxazole and trimethoprim lost meaningful U.S. market exclusivity decades ago. Bactrim and Septra were introduced in the 1970s, and current products do not depend on an unexpired composition-of-matter patent for commercial protection.
| Exclusivity category |
Current assessment |
| New chemical entity exclusivity |
Expired |
| Original composition patent |
Expired |
| Pediatric exclusivity |
Expired or no longer commercially relevant |
| Orphan exclusivity |
Not applicable to the combination as a broad antibacterial product |
| New formulation exclusivity |
No broad, commercially controlling exclusivity identified for standard tablets or suspension |
| Orange Book patent barrier |
No material blocking patent barrier for routine generic entry |
| Biosimilar pathway |
Not applicable; this is a small-molecule drug |
Patent protection for a new delivery system, taste-masked suspension, modified-release product, or device could exist separately from the legacy product. Such protection would cover the new formulation or manufacturing method, not the underlying sulfamethoxazole-trimethoprim combination.
What patents protect sulfamethoxazole and trimethoprim products?
The core drug combination is not commercially protected by a live U.S. composition patent. Historical patents associated with the original products and early formulations have expired. Current generic products are generally approved without reliance on a patent-protected active ingredient.
For a new entrant, the relevant intellectual-property categories are:
- Formulation patents covering suspension stability, taste masking, particle engineering, or excipient combinations.
- Process patents covering crystallization, particle-size control, impurity reduction, or aseptic filling.
- Packaging patents covering unit-dose delivery, child-resistant dosing systems, or reconstitution systems.
- Method-of-use patents covering a narrowly defined patient population or dosing regimen.
- Trademark and trade-dress rights covering brand names, labels, and packaging.
A standard tablet or conventional oral suspension would have low patentability. A defensible formulation requires a measurable technical effect, such as improved chemical stability, reduced sedimentation, better redispersibility, lower bitterness, reduced dosing error, or improved compatibility with enteral tubes.
How many patents cover sulfamethoxazole and trimethoprim?
The number of historical patent documents is not a useful measure of current commercial protection. The relevant question is whether an unexpired, enforceable patent claims the product, formulation, method, or manufacturing process.
For the standard products:
| Patent category |
Commercial significance |
| Core active ingredients |
Minimal; legacy protection expired |
| 400/80 mg and 800/160 mg tablets |
Low unless a new formulation is claimed |
| 200/40 mg per 5 mL suspension |
Low for conventional products |
| IV concentrate or solution |
Low for conventional products, with manufacturing complexity remaining |
| Taste-masked pediatric product |
Potentially meaningful |
| Extended-release product |
Potentially meaningful but requires clinical and bioavailability support |
| Ready-to-administer hospital product |
Potentially meaningful through formulation, packaging, or process claims |
Patent searches should distinguish expired historical patents from live continuation, divisional, formulation, and process claims. A patent family count without legal-status review can materially overstate the estate.
What excipients are used in sulfamethoxazole and trimethoprim tablets?
Tablet excipients vary by manufacturer and dosage strength. Common functional excipient classes include:
| Excipient class |
Function |
| Microcrystalline cellulose |
Diluent and compression aid |
| Povidone or copovidone |
Binder |
| Sodium starch glycolate or croscarmellose sodium |
Disintegrant |
| Magnesium stearate or stearic acid |
Lubricant |
| Colloidal silicon dioxide |
Glidant |
| Film-coating polymers |
Protection, appearance, swallowability |
| Colorants |
Product identification |
The tablet opportunity is not primarily a new excipient. It is a robust, low-cost excipient platform that supports direct compression, high-throughput manufacturing, and consistent dissolution.
Commercial differentiation may come from:
- Smaller tablets at equivalent strength.
- Improved swallowability for older adults.
- Low-lactose or lactose-free formulations.
- Dye-free formulations.
- Reduced tablet friability.
- Unit-dose packaging for institutional use.
- Scored tablets where permitted by the product specification.
- Formulations optimized for patients receiving multiple oral medicines.
The main technical risk is maintaining dissolution and content uniformity because the two active ingredients have different physicochemical properties and are combined at a 5:1 mass ratio.
What formulations are protected by sulfamethoxazole and trimethoprim patents?
Conventional formulations have limited patent strength. More defensible opportunities involve delivery problems that are visible to patients, caregivers, hospitals, or pharmacists.
Pediatric oral suspension
The oral suspension is the strongest immediate excipient opportunity. It must address:
- Sulfamethoxazole bitterness.
- Trimethoprim bitterness.
- Sedimentation and caking.
- Dose uniformity after storage.
- Redispersibility after standing.
- Chemical stability.
- Preservative tolerance.
- Syringe compatibility.
- Dosing-volume reduction.
A typical commercial suspension uses sweeteners, viscosity modifiers, surfactants, preservatives, and flavors. Public labeling for marketed products identifies excipient systems that can include sorbitol, glycerin, cellulose derivatives, polysorbates, parabens, and flavoring agents, although the exact composition differs by manufacturer.[4]
A differentiated suspension could use a polymeric taste-masking system, coated drug particles, a structured vehicle, or a higher-concentration presentation. The commercial case is strongest where the product reduces dosing volume without compromising redispersibility or bioequivalence.
Ready-to-use and unit-dose products
Ready-to-use oral doses could reduce pharmacy preparation, dosing errors, and contamination risk. Unit-dose cups or oral syringes could appeal to hospitals, long-term-care facilities, pediatric clinics, and home-care providers.
Packaging claims may provide a more practical barrier than formulation claims if the product is difficult to design around. The primary value would be operational rather than therapeutic.
IV injection
The IV product has more demanding manufacturing requirements than tablets or suspension. The label identifies concentrated excipients, including propylene glycol and alcohol, with sodium hydroxide used for pH adjustment.[5] The product is diluted before administration according to labeling.
Commercial opportunities include:
- Ready-to-dilute bags.
- Premixed IV containers.
- Low-volume hospital presentations.
- Improved compatibility labeling.
- Reduced alcohol or propylene glycol exposure, if technically and clinically feasible.
- Packaging designed for pharmacy automation.
- Extended stability after dilution.
A new IV product would need strong stability, extractables and leachables, compatibility, sterility, particulate, and container-closure data.
What manufacturing and excipient barriers affect commercial entry?
The active ingredients are inexpensive, but manufacturing quality remains important. Key barriers include:
Content uniformity
The 5:1 ratio creates a formulation challenge. Blend segregation, particle-size differences, and poor API distribution can affect low-dose trimethoprim uniformity.
Suspension stability
A commercially acceptable suspension must remain physically stable and redisperse with ordinary shaking. A product that forms a hard cake creates dosing risk and weakens substitution potential.
Chemical stability
The formulation must control pH, water activity, light exposure, oxygen exposure, and interactions with preservatives or packaging materials. Stability-indicating methods must detect degradation products and impurities.
Taste masking
Taste is a major barrier to pediatric adherence. Sweetener-only systems often fail to adequately mask the bitterness of both active ingredients. Polymer coating, ion exchange, lipid barriers, or multiparticulate systems may improve performance, but they increase manufacturing cost.
IV compatibility
The IV product must be evaluated with dilution fluids, administration sets, containers, and other medicines commonly used in hospitals. Precipitation and particulate formation can limit the value of a convenient presentation.
Supply-chain reliability
The most defensible commercial position may come from dependable supply rather than patent exclusivity. FDA drug-shortage information and manufacturer communications should be monitored because hospital buyers may prefer suppliers that maintain consistent availability.[6]
What is the Orange Book status of sulfamethoxazole and trimethoprim?
The Orange Book remains relevant for identifying reference products, therapeutic-equivalence ratings, and approved generic products. It is not a source of meaningful market exclusivity for the standard combination.
For a new abbreviated application, the likely regulatory pathway is an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the applicable reference product. For a new dosage form or materially altered formulation, a 505(b)(2) application may be more appropriate, particularly if the applicant relies partly on published literature or an established product while introducing a new delivery system.[1][7]
The key regulatory risks are:
- Failure to match dosage-form performance.
- Suspension bioequivalence complexity.
- Inadequate comparative dissolution.
- Inconsistent particle size.
- Incomplete preservative effectiveness data.
- Inadequate stability after opening.
- Labeling differences that affect substitution.
- Device performance issues for oral syringes or delivery systems.
Are there Paragraph IV challenges for sulfamethoxazole and trimethoprim?
Paragraph IV litigation is unlikely to create a significant barrier for conventional sulfamethoxazole-trimethoprim products because the relevant legacy patents have expired or do not materially block standard generic entry.
Paragraph IV activity could arise if a company obtains a later patent on:
- A novel taste-masked suspension.
- A high-concentration pediatric formulation.
- A modified-release dosage form.
- A new IV container or premixed presentation.
- A specific particle-size or crystallization process.
- A narrowly defined method of use.
Such litigation would concern the later patent, not ownership of the basic antibacterial combination. The commercial value of a Paragraph IV strategy would depend on the patent’s enforceability, claim breadth, product differentiation, and ability to support a premium price.
Which companies are challenging or competing with sulfamethoxazole and trimethoprim?
Competition is fragmented. Generic manufacturers and contract suppliers compete on acquisition cost, availability, dosage-form breadth, and regulatory reliability. The reference brands have limited pricing power because pharmacies and institutions generally source therapeutically equivalent generic products.
Clinical alternatives include nitrofurantoin, fosfomycin, fluoroquinolones, beta-lactams, and other agents selected according to infection site, susceptibility, patient characteristics, and local resistance patterns. These products compete for prescribing decisions but do not directly determine the patent status of sulfamethoxazole and trimethoprim.[3]
A manufacturer entering this market would compete against:
- Low-cost generic tablets.
- Established suspension suppliers.
- Hospital-focused injection manufacturers.
- Private-label distributors.
- Pharmacy wholesalers with contracted supply.
- Alternative antibiotics used for the same indications.
What licensing deals affect sulfamethoxazole and trimethoprim?
No major current licensing transaction is required to commercialize a conventional generic version of the combination. The product is suitable for contract development, contract manufacturing, private-label supply, and regional distribution agreements.
Potential deal structures include:
| Deal structure |
Commercial use |
| ANDA acquisition |
Fast entry through an approved or near-approved product |
| Contract manufacturing |
Lower capital investment |
| Private-label supply |
Pharmacy, hospital, or distributor channel access |
| Regional commercialization |
Local registration and distribution |
| Formulation license |
Taste masking, high-concentration suspension, or ready-to-use IV |
| Hospital supply agreement |
Volume-based purchasing and continuity commitments |
A formulation license is more likely to support pricing power than a conventional API or tablet license.
How strong is the sulfamethoxazole-trimethoprim patent estate?
The core patent estate is weak for exclusivity purposes because the combination is old, generic, and widely manufactured. The opportunity lies in product-level differentiation.
| Asset |
Patent strength |
Commercial strength |
| Conventional tablet |
Low |
Low to moderate |
| Standard oral suspension |
Low |
Moderate |
| Taste-masked pediatric suspension |
Moderate if technically differentiated |
High relative to the base product |
| Premixed IV product |
Moderate |
Moderate to high in institutional channels |
| Novel extended-release product |
Potentially high |
Uncertain; clinical development required |
| Packaging and dosing system |
Moderate |
Moderate |
| Manufacturing process |
Moderate if impurity or yield advantage is demonstrated |
Moderate |
A strong patent position would require claims tied to reproducible formulation parameters and data showing an unexpected technical benefit. Broad claims covering the mere use of ordinary sweeteners, binders, or viscosity modifiers would face validity and design-around risks.
What generic launch risks exist for sulfamethoxazole and trimethoprim?
The product has low legal launch risk but moderate execution risk.
Primary risks include:
- Price compression from multiple ANDA holders.
- Limited reimbursement differentiation.
- FDA scrutiny of suspension performance.
- API and finished-dose supply interruptions.
- Taste-related nonadherence.
- Hospital preference for established injection suppliers.
- Labeling and substitution differences.
- Low return on investment for an undifferentiated tablet.
The best launch scenarios are a pediatric suspension with superior palatability, a reliable hospital injection product, or a convenient unit-dose platform. A conventional tablet launch requires scale, low cost, and dependable distribution.
What is the commercial opportunity for excipient suppliers?
Excipient suppliers can target four areas:
- Taste-masking systems for bitter antibacterial suspensions.
- Suspending and rheology systems that improve redispersibility.
- Direct-compression platforms that support low-dose trimethoprim uniformity.
- Preservative and packaging systems that extend in-use stability.
The most attractive value proposition is not a single excipient. It is a validated platform that reduces development time and supports regulatory documentation across multiple generic customers.
Excipient suppliers should prioritize materials with established compendial status, pediatric-use history, global regulatory acceptance, and reliable supply. A technically superior excipient with limited regulatory precedent may create more development burden than commercial value.
Key Takeaways
- Sulfamethoxazole and trimethoprim is a mature generic combination with no meaningful core-product exclusivity.
- Standard tablets have limited patent and pricing potential.
- Pediatric oral suspension is the clearest excipient-driven opportunity.
- Taste masking, redispersibility, dosing-volume reduction, and preservative strategy are central formulation priorities.
- IV products offer hospital opportunities but require higher sterility, compatibility, and stability investment.
- Paragraph IV litigation is unlikely to affect conventional products.
- New formulation, process, packaging, or delivery patents could create narrower protection.
- Commercial success depends more on supply reliability, dosage-form performance, and channel access than on legacy brand recognition.
- The strongest investment case is a differentiated suspension, unit-dose product, or ready-to-use hospital presentation.
FAQs About Sulfamethoxazole and Trimethoprim Formulation and Commercialization
Can sulfamethoxazole and trimethoprim be formulated as a higher-concentration suspension?
Yes. A higher-concentration suspension could reduce dosing volume, but it would require evidence for uniformity, redispersibility, chemical stability, palatability, syringe accuracy, and bioequivalence.
Which excipient best masks the bitterness of sulfamethoxazole and trimethoprim?
No single excipient is universally optimal. Polymer-coated particles, ion-exchange systems, lipid barriers, sweeteners, flavors, and viscosity modifiers are often evaluated as combined systems.
Is a sulfamethoxazole-trimethoprim chewable tablet commercially attractive?
It could address pediatric administration, but the active ingredients’ bitterness and the need for reliable dose uniformity make taste masking and patient acceptability the main development risks.
Can a sulfamethoxazole-trimethoprim product qualify for 505(b)(2) approval?
A materially new dosage form, delivery system, or formulation may be suitable for a 505(b)(2) pathway if the application relies partly on existing findings while providing product-specific data.[7]
Are biosimilars relevant to sulfamethoxazole and trimethoprim?
No. Sulfamethoxazole and trimethoprim are synthetic small molecules. Competing products are regulated as generic drugs, not biosimilars.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Bactrim and sulfamethoxazole and trimethoprim prescribing information.
- National Library of Medicine. (2024). Sulfamethoxazole and trimethoprim drug labels. DailyMed.
- National Library of Medicine. (2024). Sulfamethoxazole and trimethoprim oral suspension labels. DailyMed.
- U.S. Food and Drug Administration. (2024). Sulfamethoxazole and trimethoprim injection prescribing information.
- U.S. Food and Drug Administration. (2024). Drug shortages database.
- U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2).
